S-14506 was originally identified and developed in France by Scientists at the Institut de Recherches Servier. S-14506 showed potent binding and antagonistic activity against the 5HT1-A receptor. It was found to work synergistically with D2 receptor antagonists and was therefore studied in animal models for depression, psychosis, and anxiety. A tritium labeled version was also studied as a potential 5HT1-A receptor PET imaging agent.